Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosisRobert Zivadinov, Omar Khan, Anthony T. Reder et al.|Neurology|2008Cited by 261
Immunomodulatory activity of interferon‐betaLloyd H. Kasper, Anthony T. Reder|Annals of Clinical and Translational Neurology|2014Cited by 165
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trialBianca Weinstock‐Guttman, Jerry S. Wolinsky, Thomas Leist et al.|Multiple Sclerosis Journal|2021Cited by 23